文献速递肝病

肝硬化患者细菌感染微生物学特征20年全地区研究

Microbiological Profile of Bacterial Infections in Patients With Cirrhosis Over Time: A 20-year Territory-wide Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-08-05

该研究基于香港全地区数据库,纳入2001至2021年173,725例次肝硬化成人住院,其中18,513例次培养阳性。革兰阴性菌占69.3%但2010至2021年比例下降,多重耐药菌占34.1%且2001至2006年上升,多重耐药感染及每年感染≥2次与院内死亡独立相关。

要点

  • 肝硬化患者多重耐药菌感染占比34.1%,且2001至2006年呈上升趋势。
  • 革兰阴性菌占69.3%,但2010至2021年比例逐年下降。
  • 多重耐药感染及每年感染≥2次与院内死亡独立相关。

核心结论

  • 肝硬化患者中抗菌药物耐药呈上升趋势,需多学科协作应对。

研究设计与样本

  • 基于香港全地区数据库的回顾性队列研究,纳入2001至2021年成人肝硬化住院患者。
  • 共纳入17,685例患者的173,725例次住院,其中7,638例患者的18,513例次培养阳性。
  • 采用连接点回归分析细菌学及抗菌药物耐药模式的时间趋势,并做患者水平多因素logistic回归。

主要发现

  • 革兰阴性菌占69.3%,但其比例从2010至2021年下降(年度百分比变化-0.6%;95%CI -1.8至-0.1)。
  • 多重耐药菌在34.1%的感染发作中分离出,2001至2006年上升(年度百分比变化6.8%;95%CI 3.0至17.7)。
  • 耐甲氧西林金黄色葡萄球菌、三代头孢耐药肠杆菌目、碳青霉烯耐药肠杆菌目、碳青霉烯耐药铜绿假单胞菌和碳青霉烯耐药不动杆菌发作数分别为1484(60.4%)、3122(28.7%)、135(1.4%)、119(6.2%)和254(40.5%)。
  • 住院期间多重耐药感染(aOR 1.56;95%CI 1.26-1.93;P<.001)与院内死亡增加独立相关。
  • 每年感染2次(aOR 1.64;95%CI 1.36-1.98;P<.001)或≥2次(aOR 2.74;95%CI 2.27-3.30;P<.001)与院内死亡增加独立相关。

临床怎么用

  • 对肝硬化住院患者应关注多重耐药菌感染风险,尤其是反复感染或既往多重耐药感染者。
  • 经验性抗菌治疗需结合当地耐药监测数据,并重视多重耐药感染对院内死亡的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Antimicrobial resistance (AMR) complicates the management of bacterial infections in cirrhosis, whereas detailed microbiology data remain scarce. This study aimed to characterize the bacteriological landscape in patients with cirrhosis and assess their impact on mortality. METHODS: All admissions of adult patients with cirrhosis between 2001 and 2021 were identified using a territory-wide database in Hong Kong. Temporal trends in bacteriology and AMR patterns were assessed using joinpoint regressions. Survival status at the last admission was assessed, and patient-level multivariable logistic regression was performed. RESULTS: A total of 173,725 admissions from 17,685 patients were included, among which 18,513 admissions from 7638 patients had positive cultures. Gram-negative bacteria predominated (69.3%), but their proportion decreased from 2010 to 2021 (annual percent change, -0.6%; 95% confidence interval [CI], -1.8 to -0.1). Multidrug-resistant organisms were isolated in 34.1% of episodes and increased during 2001 to 2006 (annual percent change, 6.8%; 95% CI, 3.0-17.7). A heterogeneous increase in resistance was observed across organisms. The total number (and prevalence of resistance among the same organism) of methicillin-resistant Staphylococcus aureus, third-generation cephalosporin-resistant Enterobacterales, carbapenem-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter episodes was 1484 (60.4%), 3122 (28.7%), 135 (1.4%), 119 (6.2%), and 254 (40.5%), respectively. Multidrug-resistant infections during admissions (adjusted odds ratio [aOR], 1.56; 95% CI, 1.26-1.93; P < .001) and a history of 2 (aOR, 1.64; 95% CI, 1.36-1.98; P < .001) or more (aOR, 2.74; 95% CI, 2.27-3.30; P < .001) infection episodes per year were independently associated with increased in-hospital mortality. CONCLUSIONS: AMR is rising in patients with cirrhosis. Multidisciplinary effort is crucial to combat AMR and manage bacterial infections in cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Cai J, Yip TC, Wong GL, et al. Microbiological Profile of Bacterial Infections in Patients With Cirrhosis Over Time: A 20-year Territory-wide Study. Clin Gastroenterol Hepatol. 2025. PMID: 40769471. doi:10.1016/j.cgh.2025.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。